蘇博特(603916.SH):子公司擬以5600萬元收購上海蘇科100%股權
格隆匯9月10日丨蘇博特(603916.SH)公佈,公司下屬控股子公司江蘇省建築工程質量檢測中心有限公司(“檢測中心”)擬收購江蘇省建築科學研究院有限公司(“建科院”)、江蘇博特新材料有限公司(“江蘇博特”)、及華勇持有的上海蘇科建築技術發展有限公司(“上海蘇科”)100%股權,交易價格為5600萬元。
收購完成後,檢測中心將派員充實上海蘇科的管理團隊和技術團隊,按照“兩個拓展”的發展理念,依託新建的科研大樓和實驗室,拓展檢測領域,提升檢測業務能力;與蘇博特的上海銷售渠道形成良好的協同效應,開拓上海建工、上海綠地等重點客户,不斷擴大市場地域、優化客户結構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.